复星医药(02196)：FCN-159 片用于治疗儿童朗格汉斯组织细胞增生症已被纳入突破性治疗药物程序

智通财经2025-05-12

智通财经APP讯，复星医药(02196)公布，根据国家药品监督管理局药品审评中心发布的公示信息，该公司控股子公司上海复星医药产业发展有限公司的 FCN-159 片(申请注册分类：化药 1 类;以下简称“该新药”)用于治疗儿童朗格汉斯组织细胞增生症已被纳入突破性治疗药物程序。该新药为该集团自主研发的创新型小分子化学药物，为 MEK1/2 选择性抑制剂，拟主要用于治疗晚期实体瘤、1 型神经纤维瘤病、...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2534722855?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-12 18:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2534722855","market":"sh","top_or_hot":-1,"title":"复星医药(02196)：FCN-159 片用于治疗儿童朗格汉斯组织细胞增生症已被纳入突破性治疗药物程序","media":"智通财经","content":"<div>\n<p>智通财经APP讯，复星医药(02196)公布，根据国家药品监督管理局药品审评中心发布的公示信息，该公司控股子公司上海复星医药产业发展有限公司的 FCN-159 片(申请注册分类：化药 1 类;以下简称“该新药”)用于治疗儿童朗格汉斯组织细胞增生症已被纳入突破性治疗药物程序。该新药为该集团自主研发的创新型小分子化学药物，为 MEK1/2 选择性抑制剂，拟主要用于治疗晚期实体瘤、1 型神经纤维瘤病、...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1292097.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>复星医药(02196)：FCN-159 片用于治疗儿童朗格汉斯组织细胞增生症已被纳入突破性治疗药物程序</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n复星医药(02196)：FCN-159 片用于治疗儿童朗格汉斯组织细胞增生症已被纳入突破性治疗药物程序\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-12 18:45 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1292097.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，复星医药(02196)公布，根据国家药品监督管理局药品审评中心发布的公示信息，该公司控股子公司上海复星医药产业发展有限公司的 FCN-159 片(申请注册分类：化药 1 类;以下简称“该新药”)用于治疗儿童朗格汉斯组织细胞增生症已被纳入突破性治疗药物程序。该新药为该集团自主研发的创新型小分子化学药物，为 MEK1/2 选择性抑制剂，拟主要用于治疗晚期实体瘤、1 型神经纤维瘤病、...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1292097.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"600196","symbol_name":"复星医药","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1292097.html","article_id":"2534722855","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2534722855","pubTimestamp":1747046711,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，复星医药(02196)公布，根据国家药品监督管理局药品审评中心发布的公示信息，该公司控股子公司上海复星医药产业发展有限公司的 FCN-159 片(申请注册分类：化药 1 类;以下简称“该新药”)用于治疗儿童朗格汉斯组织细胞增生症已被纳入突破性治疗药物程序。该新药为该集团自主研发的创新型小分子化学药物，为 MEK1/2 选择性抑制剂，拟主要用于治疗晚期实体瘤、1 型神经纤维瘤病、树突状细胞和组织细胞肿瘤、低级别脑胶质瘤等。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600196":"复星医药","BK1515":"抗疫概念","BK4123":"调查和咨询服务","02196":"复星医药","BK0196":"行业龙头","BK0239":"医药制造","LU1878469433.USD":"THREADNEEDLE (LUX) - AMERICAN SMALLER COMPANIES \"A\" (USD) ACC","BK0096":"民营医院","IE00B64QTZ34.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) ACC","FCN":"FTI咨询","BK0183":"MSCI概念","BK0188":"融资融券","BK0012":"证金概念","BK0187":"一线龙头","BK0028":"国家队","BK1191":"制药","BK0175":"白马股","BK1593":"医美概念股","BK0060":"抗癌"},"translate_title":"Fosun Pharma (02196): FCN-159 tablets for the treatment of pediatric Langerhans histiocytosis have been included in the breakthrough therapeutic drug program","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1,"02196":1,"FCN":1},"content_text":"智通财经APP讯，复星医药(02196)公布，根据国家药品监督管理局药品审评中心发布的公示信息，该公司控股子公司上海复星医药产业发展有限公司的 FCN-159 片(申请注册分类：化药 1 类;以下简称“该新药”)用于治疗儿童朗格汉斯组织细胞增生症已被纳入突破性治疗药物程序。该新药为该集团自主研发的创新型小分子化学药物，为 MEK1/2 选择性抑制剂，拟主要用于治疗晚期实体瘤、1 型神经纤维瘤病、树突状细胞和组织细胞肿瘤、低级别脑胶质瘤等。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2534722855","isCrawlerRequest":true}